Paul Conkling

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares et al. · The Lancet Oncology · 2019 · 1.7K citations · Full text

Medicine, Oncology, Metastasis +9

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

Robert M. Jotte, Paul Conkling, Craig H. Reynolds et al. · Journal of Clinical Oncology · 2010 · 176 citations

Medicine, Oncology, Pharmacology +13

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

Shirish M. Gadgeel, Rimas V. Lukas, Jerome H. Goldschmidt et al. · Lung Cancer · 2018 · 172 citations

Medicine, Oncology, Pharmacotherapy +15

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

David S. Ettinger, Robert M. Jotte, Paul Lorigan et al. · Journal of Clinical Oncology · 2010 · 124 citations

Medicine, Oncology, Pharmacology +14

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling et al. · Clinical Cancer Research · 2014 · 113 citations

Medicine, Oncology, Pharmacology +16